Blast near BJP office: Explosives supplier Danial Prakash arrested

Bengaluru, Jun 18: Former Karnataka Chief Minister and Congress leader Siddaramaiah has accused the BJP-led government of not passing the benefit of the low price of crude to the common man and urged Prime Minister Narendra Modi to take steps to bring down prices of petroleum products.

Hitting out at the BJP-led government, he termed it as "opportunistic" and said the price of petroleum products were being increased when people were facing difficulties due to COVID-19.

"It is very disheartening to witness and unprecedented opportunistic government which is trying to extract every pound and flesh from the common man, that too when the whole country is suffering from the COVID-19 pandemic. This is in the backdrop of the continuous price hike in the last 10 days," said the letter was written on Wednesday.

The Congress leader said that the policy decisions taken by the government "with respect to managing fuel sources are inconsistent with the prudent measures generally adopted".

"When the price of crude oil was remarkably low in March, April and May 2020, your government was very reluctant to pass on the benefits to the people by reducing the fuel prices proportionately, but, instead, your government continued to capitalise by increasing the excise duty," he said.

He said the government had also "failed" in the last six years to increase the oil storage capacity which could have been used for the country's advantage when the international crude oil price fell really low.

He said the government should roll back the excise duty and help in the reduction of fuel prices.

"The reduced burden will help the common man to have additional money in hand that will be spent on essential goods and services which will ultimately help them tide over these difficult times," he said.

Bengaluru, Mar 15: Karnataka government has said that as of now six cases of COVID-19 have been reported in the state, including one person who died.

"Till date six COVID-19 cases have been reported in the state including one death. The 5 Coronavirus positive cases are in isolation at the designated hospital in Bengaluru," the Karnataka government said on Sunday.

Meanwhile, the Health Department of Karnataka on Sunday said that all the family members and other contacts of the 76-year-old man who died of coronavirus in Kalaburagi are being monitored closely.

The Union Ministry of Health and Family Welfare informed that India's tally in the number of positive cases for coronavirus has reached 107 on Sunday.

New Delhi, Jun 11: The Department of Pharmaceuticals has given its nod for lifting of ban on the export of hydroxychloroquine, Union Minister D V Sadananda Gowda said on Wednesday.

India had banned export of hydroxychloroquine on March 25, with some exceptions, amid views in some quarters that the drug could be used to fight COVID-19. On April 4, it completely banned the exports without any exception.

"Department of Pharmaceuticals has approved the lifting of ban on export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20 per cent production in the domestic market," the minister of chemicals and fertilisers said in a tweet.

The Directorate General of Foreign Trade (DGFT) has been asked to issue formal notification in this regard, he added.

In another tweet, Gowda said he held discussions with representatives of pharma companies along with some of his ministerial colleagues on the challenges being faced by the industry and on the roadmap to boost exports.

"Had detailed discussion with representatives of pharma companies & association, stakeholder Ministries along with Hon Ministers @piyushGoyal  ji, @HardeepSPuri  ji, & @MansukhMandviya  ji on entire gamut of challenges faced by the industry as well as strategies to boost pharma export," Gowda tweeted.

India exported hydroxychloroquine API (active pharmaceutical ingredient) worth USD 1.22 billion in April-January 2019-20.

During the same period, exports of formulations made from hydroxychloroquine was at USD 5.50 billion.